Inovio Pharmaceuticals: A Closer Look at the Company's Future Prospects

Inovio Pharmaceuticals, a biotechnology company, is expected to breakeven in 2028, with a projected loss in 2027 and a positive profit of $28m in 2028. Industry analysts anticipate a growth rate of 52% per year, which is considered optimistic. The company has negative equity on its balance sheet, but its key fundamentals can be found on Simply Wall St.